Matsui R 1
,
Yamaguchi K 2
,
Lee JJV 3
,
Ting I 4
,
Khairilisani D 5
,
Chang J 6
Show all authors
,
Seo JM 7
,
Park I 8
,
Chee ASM 9
,
Quizon PM 10
,
Harnpramukkul U 11
,
Sem E 12
,
Nguyen T 13
,
Padhye A 14
,
Mo R 15
Affiliations
- 1 Pfizer R&D Japan, Tokyo, Japan. rie.matsui@pfizer.com
- 2 Takeda Pharmaceutical Company Limited, Osaka, Japan
- 3 Astellas Pharma Inc., Tokyo, Japan
- 4 Ferring Pharmaceuticals Ltd., Kowloon, Hong Kong
- 5 Abbott Indonesia, South Jakarta, Indonesia
- 6 Merck Sharp & Dohme, Taipei, Taiwan
- 7 KPBMA, Seoul, Korea
- 8 GE Healthcare AS Korea, Seoul, Korea
- 9 Pharmaceutical Association of Malaysia (PhAMA), Selangor, Malaysia
- 10 Pfizer, Inc. (Philippines), Makati, Philippines
- 11 Pfizer (Thailand) Limited, Bangkok, Thailand
- 12 Takeda Pharmaceuticals International AG, Singapore, Singapore
- 13 Pharma Group Vietnam, Ho Chi Minh, Vietnam
- 14 Pfizer Limited (India), Mumbai, India
- 15 Sanofi Global Regulatory Science & Policy, China & Asia team, Beijing, China
PMID: 36315399
DOI: 10.1007/s43441-022-00476-z
* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.